Sarepta price target lowered to $183 from $187 at Morgan Stanley

Morgan Stanley analyst Matthew Harrison lowered the firm’s price target on Sarepta to $183 from $187 and keeps an Overweight rating on the shares. The firm issued its biotechnology Q1 sector preview, stating that broadly for the group it does not "expect many surprises" given recently issued guidance. The firm sees investor focus being mainly on Q2 catalysts in the space.